Trial abstract · §3
SERM-DIAGNOSTIC — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Growth-hormone response to a growth-hormone-releasing hormone 1-29 challenge | Formerly marketed as a diagnostic agent; withdrawn for commercial reasons | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Sermorelin from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Injection-site reaction | 16.0 | — | Diagnostic-use data |
| Flushing | — | — | Reported transiently |
| Dysgeusia | — | — | Reported |
| Headache | — | — | Reported |
| Nausea | — | — | Reported at low incidence |
Compound Evidence Institute · CEI-TR-0146/3 · https://compoundevidence.com/trials/serm-diagnostic/results/ · retrieved 30 July 2026